What is Sagimet Biosciences Inc.'s earnings per share (EPS)?

Sagimet Biosciences Inc. (SGMT) reported diluted earnings per share of $-1.58 for fiscal year 2025. This represents a -9.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Sagimet Biosciences Inc. Financials

SGMT

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Sagimet Biosciences Inc. (SGMT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SGMT FY2025 2026-04-22

Repeated external financing, not self-funded operations, is supporting an R&D-heavy model that continues to consume cash.

A $104.8M financing inflow in FY2024 was followed by just $275K in FY2025, yet year-end cash fell to $35.0M because operating cash burn deepened to $45.7M; that combination shows the balance sheet is refreshed episodically by capital raises rather than sustained by internal cash generation.

This is a development-stage cost structure: in FY2025, R&D spending was $39.1M versus SG&A of $17.8M, so most cash use is aimed at advancing the program rather than supporting a scaled commercial organization. The operating loss therefore reflects investment intensity more than financing costs or heavy fixed production assets.

The company still looks lightly levered: FY2025 liabilities were only $5.1M against $116.5M of assets, so the immediate issue is not debt pressure. The practical constraint is cash runway, because the $35.0M cash balance was lower than one year's FY2025 operating outflow of $45.7M.

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Sagimet Biosciences Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

100

Sagimet Biosciences Inc. carries a low D/E ratio of 0.05, meaning only $0.05 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 22.82, Sagimet Biosciences Inc. holds $22.82 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Sagimet Biosciences Inc. generates a -45.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -29.3% the prior year.

Piotroski F-Score Weak

1/9

Sagimet Biosciences Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.89x

For every $1 of reported earnings, Sagimet Biosciences Inc. generates $0.89 in operating cash flow (-$45.6M OCF vs -$51.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$51.0M

YoY-12.0%

Sagimet Biosciences Inc. reported -$51.0M in net income in fiscal year 2025. This represents a decrease of 12.0% from the prior year.

EPS (Diluted)

$-1.58

YoY-9.0%

Sagimet Biosciences Inc. earned $-1.58 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 9.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$35.0M

YoY-53.8%

Sagimet Biosciences Inc. held $35.0M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-45.8%

YoY-16.6pp

Sagimet Biosciences Inc.'s ROE was -45.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 16.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$39.1M

YoY+1.6%

Sagimet Biosciences Inc. invested $39.1M in research and development in fiscal year 2025. This represents an increase of 1.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

SGMT Income Statement

Metric	FY25	FY24	FY23	FY22
Revenue	N/A	N/A	$2.0M	N/A
Cost of Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A
R&D Expenses	$39.1M+1.6%	$38.4M+94.4%	$19.8M-20.6%	$24.9M
SG&A Expenses	$17.8M+11.4%	$16.0M+23.5%	$13.0M+111.3%	$6.1M
Operating Income	-$56.9M-4.5%	-$54.5M-77.1%	-$30.7M+1.0%	-$31.1M
Interest Expense	N/A	N/A	N/A	N/A
Income Tax	$0	$0	N/A	N/A
Net Income	-$51.0M-12.0%	-$45.6M-63.5%	-$27.9M+8.6%	-$30.5M
EPS (Diluted)	$-1.58-9.0%	$-1.45+45.5%	$-2.66+98.4%	$-165.20

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$9.7M+34.2%	$7.2M-52.8%	$15.3M	N/A	$12.7M+100.4%	$6.3M+20.0%	$5.3M
SG&A Expenses	N/A	$4.6M-1.6%	$4.7M+3.4%	$4.5M	N/A	$4.2M-0.6%	$4.3M+22.0%	$3.5M
Operating Income	N/A	-$14.3M-20.2%	-$11.9M+40.0%	-$19.9M	N/A	-$16.9M-59.6%	-$10.6M-20.8%	-$8.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$12.9M-24.3%	-$10.4M+42.9%	-$18.2M	N/A	-$14.6M-80.1%	-$8.1M-22.5%	-$6.6M
EPS (Diluted)	N/A	$-0.40-25.0%	$-0.32+42.9%	$-0.56	N/A	$-0.45-80.0%	$-0.25-8.7%	$-0.23

SGMT Balance Sheet

Metric	FY25	FY24	FY23	FY22
Total Assets	$116.5M-27.3%	$160.3M+65.7%	$96.7M+192.8%	$33.0M
Current Assets	$116.4M-23.8%	$152.8M+58.1%	$96.6M+194.7%	$32.8M
Cash & Equivalents	$35.0M-53.8%	$75.8M+0.9%	$75.1M+47456.3%	$158K
Inventory	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A
Total Liabilities	$5.1M+14.5%	$4.5M-21.2%	$5.7M-97.4%	$220.0M
Current Liabilities	$5.1M+14.5%	$4.5M-21.2%	$5.7M+7.1%	$5.3M
Long-Term Debt	N/A	N/A	N/A	N/A
Total Equity	$111.4M-28.5%	$155.8M+71.1%	$91.1M+148.7%	-$186.9M
Retained Earnings	-$346.3M-17.3%	-$295.3M-18.2%	-$249.7M-12.6%	-$221.9M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$116.5M-9.3%	$128.4M-6.6%	$137.4M-6.0%	$146.2M-8.8%	$160.3M-8.3%	$174.8M-7.5%	$189.0M-2.8%	$194.5M
Current Assets	$116.4M-2.6%	$119.5M-6.1%	$127.2M-12.9%	$146.1M-4.4%	$152.8M-2.8%	$157.2M-5.7%	$166.8M-14.3%	$194.5M
Cash & Equivalents	$35.0M+7.8%	$32.5M-23.2%	$42.3M-34.6%	$64.7M-14.7%	$75.8M-1.5%	$77.0M-19.7%	$96.0M-45.7%	$176.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.1M-44.2%	$9.1M+26.2%	$7.2M+0.9%	$7.2M+61.2%	$4.5M+8.8%	$4.1M-28.6%	$5.7M+27.0%	$4.5M
Current Liabilities	$5.1M-44.2%	$9.1M+26.2%	$7.2M	N/A	$4.5M	N/A	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$111.4M-6.6%	$119.3M-8.4%	$130.2M-6.4%	$139.0M-10.8%	$155.8M-8.7%	$170.7M-6.9%	$183.3M-3.5%	$190.0M
Retained Earnings	-$346.3M-2.8%	-$336.8M-4.0%	-$323.9M-3.3%	-$313.5M-6.2%	-$295.3M-5.8%	-$279.1M-5.5%	-$264.5M-3.2%	-$256.4M

SGMT Cash Flow Statement

Metric	FY25	FY24	FY23	FY22
Operating Cash Flow	-$45.6M-7.6%	-$42.4M-78.6%	-$23.8M+3.0%	-$24.5M
Capital Expenditures	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A
Investing Cash Flow	$4.6M+107.4%	-$61.7M-590.3%	$12.6M+139.3%	-$32.0M
Financing Cash Flow	$275K-99.7%	$104.8M+21.6%	$86.2M+118137.0%	-$73K
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$11.8M-16.2%	-$10.2M-11.9%	-$9.1M+37.4%	-$14.5M-31.9%	-$11.0M+43.7%	-$19.6M-247.3%	-$5.6M+9.2%	-$6.2M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$14.4M+19044.0%	$75K+100.6%	-$13.3M-489.4%	$3.4M-65.4%	$9.8M+1478.5%	$624K+100.8%	-$75.2M-2605.2%	$3.0M
Financing Cash Flow	$0-100.0%	$274K	N/A	N/A	$0	$0+100.0%	-$27K-100.0%	$104.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SGMT Financial Ratios

Metric	FY25	FY24	FY23	FY22
Gross Margin	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	-1537.0%	N/A
Net Margin	N/A	N/A	-1393.8%	N/A
Return on Equity	-45.8%-16.6pp	-29.3%+1.4pp	-30.6%	N/A
Return on Assets	-43.8%-15.4pp	-28.4%+0.4pp	-28.8%+63.5pp	-92.3%
Current Ratio	22.82-11.5	34.30+17.2	17.09+10.9	6.21
Debt-to-Equity	0.05+0.0	0.03-0.0	0.06+1.2	-1.18
FCF Margin	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-10.8%-2.8pp	-8.0%+5.1pp	-13.1%	N/A	-8.6%-4.1pp	-4.4%-0.9pp	-3.5%
Return on Assets	N/A	-10.1%-2.5pp	-7.6%+4.9pp	-12.4%	N/A	-8.4%-4.1pp	-4.3%-0.9pp	-3.4%
Current Ratio	22.82+9.8	13.06-4.5	17.55	N/A	34.30	N/A	N/A	N/A
Debt-to-Equity	0.05-0.0	0.08+0.0	0.060.0	0.05+0.0	0.030.0	0.020.0	0.030.0	0.02
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Silence Therapeutics Plc SLN

$365.1M

Neumora Therapeutics Inc NMRA

$423.8M

Third Harmonic Bio Inc THRD

$242.8M

AC Immune ACIU

$292.1M

Proqr Therapeuti PRQR

$182.8M

Frequently Asked Questions

Is Sagimet Biosciences Inc. profitable?

No, Sagimet Biosciences Inc. (SGMT) reported a net income of -$51.0M in fiscal year 2025.

What is Sagimet Biosciences Inc.'s return on equity (ROE)?

Sagimet Biosciences Inc. (SGMT) has a return on equity of -45.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Sagimet Biosciences Inc.'s operating cash flow?

Sagimet Biosciences Inc. (SGMT) generated -$45.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Sagimet Biosciences Inc.'s total assets?

Sagimet Biosciences Inc. (SGMT) had $116.5M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Sagimet Biosciences Inc. spend on research and development?

Sagimet Biosciences Inc. (SGMT) invested $39.1M in research and development during fiscal year 2025.

What is Sagimet Biosciences Inc.'s current ratio?

Sagimet Biosciences Inc. (SGMT) had a current ratio of 22.82 as of fiscal year 2025, which is generally considered healthy.

What is Sagimet Biosciences Inc.'s debt-to-equity ratio?

Sagimet Biosciences Inc. (SGMT) had a debt-to-equity ratio of 0.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Sagimet Biosciences Inc.'s return on assets (ROA)?

Sagimet Biosciences Inc. (SGMT) had a return on assets of -43.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Sagimet Biosciences Inc.'s cash runway?

Based on fiscal year 2025 data, Sagimet Biosciences Inc. (SGMT) had $35.0M in cash against an annual operating cash burn of $45.6M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Sagimet Biosciences Inc.'s Piotroski F-Score?

Sagimet Biosciences Inc. (SGMT) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Sagimet Biosciences Inc.'s earnings high quality?

Sagimet Biosciences Inc. (SGMT) has an earnings quality ratio of 0.89x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Sagimet Biosciences Inc.?

Sagimet Biosciences Inc. (SGMT) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.